1. Updates on Emerging GLP-1 Receptor Agonists

2. This program will include a discussion of off-label treatment and investigational agents and devices not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Adherence to Treatment Regimens

5. Overcoming Barriers to Treatment Adherence

6. Choosing the Best-Suited GLP-1 RAs for the Patient

7. Investigational GLP-1 RAs

8. How Are the Emerging GLP-1 Receptor Agonists Different?

9. Once-Weekly GLP-1 RA Semaglutide

10. Oral GLP-1 RA Semaglutide

11. ITCA 650 Continuous Delivery of Exenatide

12. Emerging GLP-1 Receptor Agonists

13. SUSTAIN-1: Safety and Efficacy of Once-Weekly Semaglutide Monotherapy vs Placebo

14. SUSTAIN-2: Safety and Efficacy of Once-Weekly Semaglutide vs Sitagliptin as Add-On to MET, TZD, or Both

15. Glycemic Control Demonstrated in SUSTAIN 1 to 5 Clinical Trials

16. SUSTAIN-6 CV Outcomes of Semaglutide

17. Updates From ADA on Retinopathy Findings

18. Safety Data

19. Dose Relationship of Oral Semaglutide on Glycemic Control and Body Weight

20. Emerging GLP-1 Receptor Agonists

21. FREEDOM-1 Study Design and Inclusion Criteria

22. FREEDOM-1 Safety and Efficacy Results at Week 39

23. FREEDOM-1 Substudy High Baseline HbA1c

24. FREEDOM-1 AEs

25. FREEDOM-2: Safety and Efficacy of ITCA 650 vs Sitagliptin With Background Metformin

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)